caffeine has been researched along with Reperfusion Injury in 19 studies
Reperfusion Injury: Adverse functional, metabolic, or structural changes in tissues that result from the restoration of blood flow to the tissue (REPERFUSION) following ISCHEMIA.
| Excerpt | Relevance | Reference |
|---|---|---|
| "One week of oral treatment with the nucleoside uptake inhibitor dipyridamole (200 mg, slow release, twice daily) significantly limits ischemia-reperfusion injury in humans in vivo, as assessed by technetium Tc 99m-labeled annexin A5 scintigraphy of forearm skeletal muscle." | 7.73 | Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans. ( Boerman, OC; Engbersen, R; Oyen, WJ; Ramakers, BP; Riksen, NP; Rongen, GA; Smits, P; Van den Broek, PH, 2005) |
| "Dipyridamole (DYP) is an anti-platelet agent with marked vasodilator, anti-oxidant, and anti-inflammatory activity." | 5.43 | Dipyridamole attenuates ischemia reperfusion induced acute kidney injury through adenosinergic A1 and A2A receptor agonism in rats. ( Buttar, HS; Kaur, T; Mohey, V; Pathak, D; Puri, N; Singh, AP; Singh, M, 2016) |
| "Treatment with theanine (1 mg/kg body mass, intraperitoneal injection) alone significantly reduced cerebral infarction induced by cerebral ischemia-reperfusion, but caffeine (10 mg/kg, intravenous administration) alone only had a marginal effect." | 5.39 | Beneficial synergistic effects of concurrent treatment with theanine and caffeine against cerebral ischemia-reperfusion injury in rats. ( Feng, Y; Gou, L; Ling, X; Liu, Y; Sun, L; Tian, X; Wang, L; Yin, X, 2013) |
| "Rosuvastatin increases extracellular adenosine formation, which provides protection against ischemia-reperfusion injury in humans in vivo." | 5.14 | Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection. ( Boerman, OC; Dekker, D; Meijer, P; Oyen, WJ; Rongen, GA; Scheffer, GJ; Smits, P; van den Broek, PH; Wouters, CW, 2009) |
| "One week of oral treatment with the nucleoside uptake inhibitor dipyridamole (200 mg, slow release, twice daily) significantly limits ischemia-reperfusion injury in humans in vivo, as assessed by technetium Tc 99m-labeled annexin A5 scintigraphy of forearm skeletal muscle." | 3.73 | Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans. ( Boerman, OC; Engbersen, R; Oyen, WJ; Ramakers, BP; Riksen, NP; Rongen, GA; Smits, P; Van den Broek, PH, 2005) |
| "Transient retinal ischemia is a major complication of retinal degenerative diseases and contributes to visual impairment and blindness." | 1.46 | Treatment with A ( Aires, ID; Ambrósio, AF; Baqi, Y; Boia, R; Cunha, RA; Elvas, F; Madeira, MH; Müller, CE; Rodrigues-Neves, AC; Santiago, AR; Szabó, EC; Tomé, ÂR; Tralhão, P, 2017) |
| "Dipyridamole (DYP) is an anti-platelet agent with marked vasodilator, anti-oxidant, and anti-inflammatory activity." | 1.43 | Dipyridamole attenuates ischemia reperfusion induced acute kidney injury through adenosinergic A1 and A2A receptor agonism in rats. ( Buttar, HS; Kaur, T; Mohey, V; Pathak, D; Puri, N; Singh, AP; Singh, M, 2016) |
| "Caffeine displays a broad array of actions on the brain." | 1.40 | Effects of caffeine on neuronal apoptosis in neonatal hypoxic-ischemic brain injury. ( Daglioglu, YK; Erdogan, S; Kilicdag, H; Zorludemir, S, 2014) |
| "Treatment with theanine (1 mg/kg body mass, intraperitoneal injection) alone significantly reduced cerebral infarction induced by cerebral ischemia-reperfusion, but caffeine (10 mg/kg, intravenous administration) alone only had a marginal effect." | 1.39 | Beneficial synergistic effects of concurrent treatment with theanine and caffeine against cerebral ischemia-reperfusion injury in rats. ( Feng, Y; Gou, L; Ling, X; Liu, Y; Sun, L; Tian, X; Wang, L; Yin, X, 2013) |
| "Adenosine treatment after ischemia protected renal function and improved tubular histology." | 1.31 | Systemic adenosine given after ischemia protects renal function via A(2a) adenosine receptor activation. ( Emala, CW; Lee, HT, 2001) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 5 (26.32) | 18.2507 |
| 2000's | 7 (36.84) | 29.6817 |
| 2010's | 7 (36.84) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Boia, R | 1 |
| Elvas, F | 1 |
| Madeira, MH | 1 |
| Aires, ID | 1 |
| Rodrigues-Neves, AC | 1 |
| Tralhão, P | 1 |
| Szabó, EC | 1 |
| Baqi, Y | 1 |
| Müller, CE | 1 |
| Tomé, ÂR | 1 |
| Cunha, RA | 1 |
| Ambrósio, AF | 1 |
| Santiago, AR | 1 |
| Muhammad, M | 1 |
| El-Ta'alu, AB | 1 |
| Mohammed, MA | 1 |
| Yarube, IU | 1 |
| Nuhu, JM | 1 |
| Yusuf, I | 1 |
| Daneji, UA | 1 |
| Sun, L | 1 |
| Tian, X | 1 |
| Gou, L | 1 |
| Ling, X | 1 |
| Wang, L | 1 |
| Feng, Y | 1 |
| Yin, X | 1 |
| Liu, Y | 2 |
| Kilicdag, H | 1 |
| Daglioglu, YK | 1 |
| Erdogan, S | 1 |
| Zorludemir, S | 1 |
| Chou, WC | 1 |
| Kao, MC | 1 |
| Yue, CT | 1 |
| Tsai, PS | 1 |
| Huang, CJ | 1 |
| Puri, N | 1 |
| Mohey, V | 1 |
| Singh, M | 1 |
| Kaur, T | 1 |
| Pathak, D | 1 |
| Buttar, HS | 1 |
| Singh, AP | 1 |
| Meijer, P | 1 |
| Oyen, WJ | 3 |
| Dekker, D | 1 |
| van den Broek, PH | 2 |
| Wouters, CW | 1 |
| Boerman, OC | 3 |
| Scheffer, GJ | 1 |
| Smits, P | 3 |
| Rongen, GA | 3 |
| Saini-Chohan, HK | 1 |
| Dhalla, NS | 1 |
| Li, Q | 1 |
| Jiao, J | 1 |
| Zhang, C | 1 |
| Lou, J | 1 |
| Riksen, NP | 2 |
| Ramakers, BP | 2 |
| Engbersen, R | 1 |
| Chen, L | 1 |
| Lu, XY | 1 |
| Li, J | 1 |
| Fu, JD | 1 |
| Zhou, ZN | 1 |
| Yang, HT | 1 |
| Zhou, Z | 1 |
| Jaspers, R | 1 |
| Brouwer, RM | 1 |
| Steinmetz, N | 1 |
| Yeung, HM | 1 |
| Kravtsov, GM | 1 |
| Ng, KM | 1 |
| Wong, TM | 1 |
| Fung, ML | 1 |
| Morton, JW | 1 |
| Duncan, CJ | 1 |
| Phillis, JW | 1 |
| Gao, H | 1 |
| Korthuis, RJ | 1 |
| Benoit, JN | 1 |
| Li, B | 1 |
| Rosenbaum, PS | 1 |
| Jennings, NM | 1 |
| Maxwell, KM | 1 |
| Roth, S | 1 |
| Schreieck, J | 1 |
| Richardt, G | 1 |
| Lee, HT | 1 |
| Emala, CW | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Does Rosuvastatin Reduce Ischemia/Reperfusion Injury in Humans In-Vivo? A Randomized Double Blind Placebo Controlled Trial[NCT00315510] | Phase 2 | 20 participants | Interventional | 2006-04-30 | Completed | ||
| Does Caffeine Reduce Rosuvastatin-Induced Protection Against Ischemia-Reperfusion Injury?[NCT00457652] | Phase 4 | 24 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Rosuvastatin Augments Dipyridamole Induced Vasodilation by Increased Adenosine Receptor Stimulation.[NCT00554138] | 24 participants (Actual) | Interventional | 2007-11-30 | Completed | |||
| Short Term Statin Treatment and Endothelial Dysfunction Due to Ischemia and Reperfusion Injury[NCT00987974] | Phase 4 | 48 participants (Anticipated) | Interventional | 2009-09-30 | Completed | ||
| Does a Seven Day Treatment With Dipyridamole Induce Protection Against Ischemia-Reperfusion Injury?[NCT00457405] | Phase 4 | 10 participants (Actual) | Interventional | 2007-06-30 | Completed | ||
| Does Caffeine Reduce Dipyridamole-Induced Protection Against Ischemia-Reperfusion Injury?[NCT00430170] | Phase 4 | 20 participants (Actual) | Interventional | 2007-01-31 | Completed | ||
| Caffeine Reduces Acute Ischemic Preconditioning[NCT00184912] | 24 participants | Interventional | 2003-09-30 | Completed | |||
| The Effect of Eplerenone on Ischemia Reperfusion Injury in Human Myocardium (EPLICARD Study)[NCT02118753] | 24 participants (Actual) | Interventional | 2014-03-31 | Completed | |||
| The Effect of Aminophylline on Preventing Acute Kidney Injury in Pediatric Patients Undergoing Open Heart Surgery[NCT03897335] | Phase 3 | 80 participants (Anticipated) | Interventional | 2019-02-07 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 trials available for caffeine and Reperfusion Injury
| Article | Year |
|---|---|
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Rosuvastatin increases extracellular adenosine formation in humans in vivo: a new perspective on cardiovascular protection.
Topics: Adenosine; Administration, Oral; Annexin A5; Caffeine; Dipyridamole; Dose-Response Relationship, Dru | 2009 |
Caffeine prevents protection in two human models of ischemic preconditioning.
Topics: Adult; Annexin A5; Caffeine; Central Nervous System Stimulants; Double-Blind Method; Humans; Ischemi | 2006 |
Caffeine prevents protection in two human models of ischemic preconditioning.
Topics: Adult; Annexin A5; Caffeine; Central Nervous System Stimulants; Double-Blind Method; Humans; Ischemi | 2006 |
Caffeine prevents protection in two human models of ischemic preconditioning.
Topics: Adult; Annexin A5; Caffeine; Central Nervous System Stimulants; Double-Blind Method; Humans; Ischemi | 2006 |
Caffeine prevents protection in two human models of ischemic preconditioning.
Topics: Adult; Annexin A5; Caffeine; Central Nervous System Stimulants; Double-Blind Method; Humans; Ischemi | 2006 |
17 other studies available for caffeine and Reperfusion Injury
| Article | Year |
|---|---|
Treatment with A
Topics: Adenosine; Adenosine A2 Receptor Antagonists; Animals; Caffeine; Humans; Inflammation; Ischemia; Mal | 2017 |
Effect of Caffeine on Serum Tumour Necrosis Factor Alpha and Lactate Dehydrogenase in Wistar Rats Exposed to Cerebral Ischaemia-reperfusion Injury.
Topics: Animals; Caffeine; Disease Models, Animal; Inflammation; L-Lactate Dehydrogenase; Liver; Male; Rats, | 2018 |
Beneficial synergistic effects of concurrent treatment with theanine and caffeine against cerebral ischemia-reperfusion injury in rats.
Topics: Animals; Antioxidants; Brain Edema; Brain Ischemia; Caffeine; Cerebral Cortex; Cerebral Infarction; | 2013 |
Effects of caffeine on neuronal apoptosis in neonatal hypoxic-ischemic brain injury.
Topics: Animals; Animals, Newborn; Apoptosis; Brain; Caffeine; Disease Models, Animal; Female; Hypoxia-Ische | 2014 |
Caffeine Mitigates Lung Inflammation Induced by Ischemia-Reperfusion of Lower Limbs in Rats.
Topics: Animals; Caffeine; Lower Extremity; Lung; Male; Oxidative Stress; Peroxidase; Pneumonia; Rats; Rats, | 2015 |
Dipyridamole attenuates ischemia reperfusion induced acute kidney injury through adenosinergic A1 and A2A receptor agonism in rats.
Topics: Acute Kidney Injury; Adenosine A1 Receptor Agonists; Adenosine A1 Receptor Antagonists; Adenosine A2 | 2016 |
Attenuation of ischemia-reperfusion-induced alterations in intracellular Ca2+ in cardiomyocytes from hearts treated with N-acetylcysteine and N-mercaptopropionylglycine.
Topics: Acetylcysteine; Animals; Caffeine; Calcium; Cardiotonic Agents; Cell Survival; Dose-Response Relatio | 2009 |
Assessment of effects of IR and IPC on activities of cytochrome P450 isozymes in rats by a five-drug cocktail approach.
Topics: Animals; Caffeine; Chlorzoxazone; Cytochrome P-450 Enzyme System; Drug Combinations; Drug Interactio | 2014 |
Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans.
Topics: Administration, Oral; Adult; Annexin A5; Blood Pressure; Caffeine; Dipyridamole; Drug Administration | 2005 |
Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans.
Topics: Administration, Oral; Adult; Annexin A5; Blood Pressure; Caffeine; Dipyridamole; Drug Administration | 2005 |
Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans.
Topics: Administration, Oral; Adult; Annexin A5; Blood Pressure; Caffeine; Dipyridamole; Drug Administration | 2005 |
Oral therapy with dipyridamole limits ischemia-reperfusion injury in humans.
Topics: Administration, Oral; Adult; Annexin A5; Blood Pressure; Caffeine; Dipyridamole; Drug Administration | 2005 |
Intermittent hypoxia protects cardiomyocytes against ischemia-reperfusion injury-induced alterations in Ca2+ homeostasis and contraction via the sarcoplasmic reticulum and Na+/Ca2+ exchange mechanisms.
Topics: Altitude; Animals; Caffeine; Calcium; Calcium-Transporting ATPases; Homeostasis; Hypoxia; Male; Musc | 2006 |
Chronic intermittent hypoxia alters Ca2+ handling in rat cardiomyocytes by augmented Na+/Ca2+ exchange and ryanodine receptor activities in ischemia-reperfusion.
Topics: Animals; Body Weight; Caffeine; Calcium; Electrophysiology; Gene Expression Regulation; Heart; Heart | 2007 |
Effect of osmotic pressure on cellular damage in the perfused rat kidney.
Topics: Animals; Caffeine; Calcium; In Vitro Techniques; Kidney; L-Lactate Dehydrogenase; Mannitol; Osmotic | 1994 |
The effects of selective A1 and A2a adenosine receptor antagonists on cerebral ischemic injury in the gerbil.
Topics: Animals; Behavior, Animal; Caffeine; Carotid Arteries; Cerebral Cortex; Cerebrovascular Disorders; D | 1995 |
Effects of hypoxia/reoxygenation on aortic vasoconstrictor responsiveness.
Topics: Animals; Aorta, Thoracic; Caffeine; Catalase; Endothelium, Vascular; Enzyme Inhibitors; Free Radical | 1996 |
Differing roles of adenosine receptor subtypes in retinal ischemia-reperfusion injury in the rat.
Topics: Animals; Caffeine; Electroretinography; Purinergic P1 Receptor Antagonists; Rats; Rats, Sprague-Dawl | 1999 |
Endogenous adenosine reduces the occurrence of ischemia-induced ventricular fibrillation in rat heart.
Topics: Adenine; Adenosine; Aminoimidazole Carboxamide; Animals; Caffeine; Creatine Kinase; Electrocardiogra | 1999 |
Systemic adenosine given after ischemia protects renal function via A(2a) adenosine receptor activation.
Topics: Adenosine; Analysis of Variance; Animals; Bucladesine; Caffeine; Kidney; Male; Purinergic P1 Recepto | 2001 |